Medication Management Considerations in COPD

Jeffrey D. Dunn, PharmD, MBA, leads a panel discussion on disease and treatment landscapes for COPD.

Social and economic burdens affecting patients with COPD provide significant obstacles to optimizing care.

Social determinants of health (SDoH) can create major barriers for access to care.

The role of combination therapy is explored for the treatment of COPD.

Inhaled corticosteroids (ICSs) are a key incorporation to COPD treatment strategies.

Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA).

An expert panel discusses appropriate transitions and adjustments to COPD treatment approaches.

Patient education is critical for self-monitoring of COPD disease progression.

Treatment pathways, including escalation and de-escalation of therapy, for patients with COPD are explored by a panel of medical experts.

Inhaler technique informs health care outcomes in COPD management and should be a primary focus in patient education priorities.

Selecting appropriate inhalers based on individual characteristics and shared decision-making is crucial for optimizing care for patients with COPD.

Nonmedication COPD strategies, such as pulmonary rehabilitation, are highlighted.

Cost drivers and payer considerations are emphasized for treatment of patients with chronic obstructive pulmonary disease.

Medical experts provide their closing thoughts on the chronic obstructive pulmonary disease treatment landscape.